Innovative scientific approaches have facilitated significant progress in drug development during recent decades, offering amazing new treatment options to patients across a range of chronic diseases. However, safety and tolerability of drug candidates and newly approved drugs often remain a key concern, leading to labelling restrictions, black box warnings, and withdrawal of otherwise promising innovative medicines.
The TransBioLine project aims to develop novel safety biomarkers that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, providing to the scientific community, industry and patients with detailed data across a large spectrum of advanced safety biomarkers.

Latest News

TransBioLine attended the closing meeting of eTRANSAFE

March 7th, 2023|Latest News|

On the 23rd of February, Sophia Samodelov, TransBioLine Project coordinator, participated in the closing meeting of eTRANSAFE Project “Towards a Quantum leap in drug safety assessment”. eTRANSAFE (enhancing translational safety assessment through integrative knowledge management) is an IMI Project intended to develop an integrative data infrastructure and innovative computational methods [...]

New publication from University of Nottingham

February 2nd, 2023|Latest News, Publications|

  Millions of people with rheumatoid arthritis and psoriasis could benefit from Nottingham biomarker research. Nottingham researchers found its side effects are less likely than previously thought and are calling for guidelines affecting the use of methotrexate to be reviewed. Doctors have used the immuno-suppressant since 1947 and around 1.3 million [...]

TransBioLine promises a decisive advance in biomarker discovery, development, validation, regulatory qualification and application, and bring about a fundamental change in the way drug safety is monitored in clinical trials, and toxicities are diagnosed and managed in clinical practice.

Funding period: 01/02/2019 to 31/01/2024. Years: 5 (2019-24)
EFPIA companies: 7. Academic & commercial partners: 22
Total Budget: EUR 28 Million
IMI contribution: EUR 14 Million (in cash).  EFPIA contribution: EUR 14 Million (in kind)
Project Coordinator: University of Zurich. Project Leader: Pfizer LTD